U.S. Markets closed

Aquestive Therapeutics, Inc. (AQST)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.5400-0.0300 (-1.17%)
At close: 04:00PM EST
2.5900 +0.05 (+1.97%)
After hours: 07:41PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5700
Bid2.5200 x 1800
Ask2.6400 x 3100
Day's Range2.4800 - 2.6400
52 Week Range2.4800 - 6.9970
Avg. Volume773,244
Market Cap102.017M
Beta (5Y Monthly)3.33
PE Ratio (TTM)N/A
EPS (TTM)-1.7010
Earnings DateMar 07, 2022 - Mar 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
  • GlobeNewswire

    Aquestive Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

    WARREN, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10th to January 13th. The Aquestive team is scheduled to a hold a presentation that will be available on demand from January

  • Motley Fool

    Why Aquestive Therapeutics Dived by 29% Today

    Aquestive Therapeutics (NASDAQ: AQST) was one of the steeper decliners among biotech stocks Tuesday. The company's shares plummeted more than 29% on a rather discouraging piece of news about one of its top drug candidates. Late Monday night, Aquestive disclosed that it had received notification from the Food and Drug Administration (FDA) regarding its Libervant Buccal Film pipeline drug.

  • MarketWatch

    Aquestive stock falls as FDA delays decision on experimental seizure treatment

    Shares of Aquestive Therapeutics Inc. tumbled 28.4% in premarket trading after the company said Monday that the Food and Drug Administration is delaying the review of its still-investigational seizure treatment. The regulator was expected to announce its decision about whether to approve the therapy by Dec. 23; the FDA said in the notice that it is "currently unable to provide an estimate of the timing of an expected action." The FDA is not requiring any additional information from Aquestive at